JP2016505635A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505635A5
JP2016505635A5 JP2015554209A JP2015554209A JP2016505635A5 JP 2016505635 A5 JP2016505635 A5 JP 2016505635A5 JP 2015554209 A JP2015554209 A JP 2015554209A JP 2015554209 A JP2015554209 A JP 2015554209A JP 2016505635 A5 JP2016505635 A5 JP 2016505635A5
Authority
JP
Japan
Prior art keywords
seq
nos
cell
tcr
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015554209A
Other languages
English (en)
Japanese (ja)
Other versions
JP6639233B2 (ja
JP2016505635A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/051726 external-priority patent/WO2014118236A2/en
Publication of JP2016505635A publication Critical patent/JP2016505635A/ja
Publication of JP2016505635A5 publication Critical patent/JP2016505635A5/ja
Application granted granted Critical
Publication of JP6639233B2 publication Critical patent/JP6639233B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015554209A 2013-01-29 2014-01-29 Mage−a1を認識する高結合活性結合分子 Active JP6639233B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13153081 2013-01-29
EP13153081.8 2013-01-29
PCT/EP2014/051726 WO2014118236A2 (en) 2013-01-29 2014-01-29 High avidity antigen recognizing constructs

Publications (3)

Publication Number Publication Date
JP2016505635A JP2016505635A (ja) 2016-02-25
JP2016505635A5 true JP2016505635A5 (OSRAM) 2017-03-09
JP6639233B2 JP6639233B2 (ja) 2020-02-05

Family

ID=47623953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015554209A Active JP6639233B2 (ja) 2013-01-29 2014-01-29 Mage−a1を認識する高結合活性結合分子

Country Status (13)

Country Link
US (3) US10377808B2 (OSRAM)
EP (2) EP3747899A3 (OSRAM)
JP (1) JP6639233B2 (OSRAM)
CN (1) CN105377886B (OSRAM)
AU (2) AU2014211454B2 (OSRAM)
CA (1) CA2899679C (OSRAM)
DK (1) DK2951202T3 (OSRAM)
ES (1) ES2804538T3 (OSRAM)
HU (1) HUE050390T2 (OSRAM)
PL (1) PL2951202T3 (OSRAM)
PT (1) PT2951202T (OSRAM)
SI (1) SI2951202T1 (OSRAM)
WO (1) WO2014118236A2 (OSRAM)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104843A1 (en) 2011-02-06 2012-08-09 Yeda Research And Development Co.Ltd. At The Weizmann Institute Of Science Affinity maturated t cell receptors and use thereof
JP6712261B2 (ja) * 2014-08-04 2020-06-24 フレッド ハッチンソン キャンサー リサーチ センター Wt−1に特異的なt細胞免疫治療
GB201417803D0 (en) 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
US12364757B2 (en) * 2015-10-01 2025-07-22 Ospedale San Raffaele S.R.L TCR and uses thereof
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520544D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3219800A1 (en) 2016-03-15 2017-09-20 Max-Delbrück-Centrum Für Molekulare Medizin A transposon-based transfection system for primary cells
CN106749620B (zh) * 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
DK3440105T3 (da) * 2016-04-08 2022-06-13 Immunocore Ltd T-cellereceptorer
CN106084042B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗MAGEA1的全分子IgG抗体及其应用
EP3515935A4 (en) * 2016-09-23 2019-09-04 Lion TCR Pte. Ltd. HBV-Antigen specific binding molecules and fragments thereof
DE102016123847B3 (de) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
MY192819A (en) * 2016-12-08 2022-09-12 Immatics Biotechnologies Gmbh Novel t cell receptors and immune therapy using the same
CN108250289B (zh) * 2016-12-28 2021-10-08 香雪生命科学技术(广东)有限公司 源自于mage b6的肿瘤抗原短肽
BR112019018863A8 (pt) * 2017-03-15 2023-05-02 Hutchinson Fred Cancer Res Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos
CN108929378B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术(广东)有限公司 一种识别prame抗原的t细胞受体及编码该受体的核酸
WO2019046818A1 (en) 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER
GB2596461B (en) * 2019-02-20 2023-09-27 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
CA3131138A1 (en) 2019-03-06 2020-09-10 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
TWI850360B (zh) 2019-04-04 2024-08-01 德商梅迪基因免疫治療公司 黑色素瘤相關抗原1(magea1)特異性t細胞受體及其用途
PE20220231A1 (es) 2019-06-25 2022-02-07 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso
EP3997116A1 (en) * 2019-07-09 2022-05-18 Medigene Immunotherapies GmbH Magea10 specific t cell receptors and their use
GB201915282D0 (en) * 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
BR112022014623A2 (pt) 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
CN113684258B (zh) * 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
JP7781085B2 (ja) * 2020-06-25 2025-12-05 ザ・メソジスト・ホスピタル 抗原特異的t細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法
IL276599A (en) * 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN112279908B (zh) * 2020-10-23 2024-03-19 魏放 识别ebv抗原短肽的t细胞受体及其应用
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
WO2023083864A1 (en) 2021-11-09 2023-05-19 T-Knife Gmbh Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN114539386B (zh) * 2022-04-27 2022-07-26 恒瑞源正(广州)生物科技有限公司 Mage-a1特异性t细胞受体及其用途
CA3260083A1 (en) 2022-07-01 2024-01-04 Gilead Sciences Inc CD73 COMPOUNDS
CN120476137A (zh) 2022-08-18 2025-08-12 英美偌科有限公司 对mage a4具有特异性的t细胞受体融合蛋白
US20240254118A1 (en) 2022-12-22 2024-08-01 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
CN121079300A (zh) 2023-04-21 2025-12-05 吉利德科学公司 Prmt5抑制剂及其用途
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025027087A1 (en) 2023-07-31 2025-02-06 T-Knife Gmbh A chimeric human cd8 co-receptor, a nucleic acid encoding the chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease
WO2025027088A1 (en) 2023-07-31 2025-02-06 T-Knife Gmbh An enhanced chimeric human cd8 co-receptor, a nucleic acid encoding the enhanced chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease
WO2025045752A1 (en) 2023-08-25 2025-03-06 T-Knife Gmbh Chimeric human cd 95 switch receptor, t-cell expressing said receptor together with an engineered t-cell receptor, respective vectors, kits, pharmaceutical compositions and methods for treating a patient having a disease
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096983A1 (en) * 2023-11-02 2025-05-08 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025146286A1 (en) 2024-01-04 2025-07-10 Immunoscape Pte. Ltd. Human t cell receptors and uses thereof
WO2025190565A1 (en) 2024-03-13 2025-09-18 T-Knife Gmbh A chimeric programmed cell death protein 1 receptor
WO2025191067A1 (en) 2024-03-13 2025-09-18 T-Knife Gmbh A chimeric transmembrane receptor comprising at least one t-cell immunoreceptor with ig and itim domains (tigit) polypeptide region, t-cells expressing the chimeric human tigit switch receptor, vectors with nucleic acids encoding for the tigit receptor, kits for preparing the t-cells, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease and for increasing cytotoxicity of a t-cell in adoptive cell therapy
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1812095A (en) 1994-02-23 1995-09-11 Akzo Nobel N.V. A t cell receptor sequence specifically associated with an immune disease
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors

Similar Documents

Publication Publication Date Title
JP2016505635A5 (OSRAM)
JP2019511222A5 (OSRAM)
JP2018535668A5 (OSRAM)
CN105384825B (zh) 一种基于单域抗体的双特异性嵌合抗原受体及其应用
HRP20241228T1 (hr) T stanični receptori i imunološka terapija uporabom istih protiv pram pozitivnih karcinoma
KR20230079259A (ko) Kras 돌연변이 특이적 t세포 수용체의 스크리닝 및 항종양 용도
JP2020500523A5 (OSRAM)
JP2020532965A5 (OSRAM)
JP2020511152A5 (OSRAM)
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
FI3430030T3 (fi) Transfektoituja t-soluja ja t-solureseptoreita käytettäviksi syöpien immunoterapiassa
FI3250592T3 (fi) Transtyretiinin vastaisia vasta-aineita
JP2018527919A5 (OSRAM)
JP2020500525A5 (OSRAM)
JP2017528158A5 (OSRAM)
JP2012525128A5 (OSRAM)
FI3294333T4 (fi) Klaudiini-18.2-spesifiset immunoreseptorit ja t-soluepitoopit
JP2017029157A5 (OSRAM)
JP2018509163A5 (OSRAM)
JP2013107899A5 (OSRAM)
JP2014509841A5 (OSRAM)
JP2015525208A5 (OSRAM)
JP2012254092A5 (OSRAM)
JP2018530331A5 (OSRAM)
CN112480239B (zh) 人乳头瘤病毒特异性t细胞受体及其抗肿瘤用途